Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verlinden, L.
Right arrow Articles by Bouillon, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verlinden, L.
Right arrow Articles by Bouillon, R.
[Cancer Research 60, 2673-2679, May 15, 2000]
© 2000 American Association for Cancer Research


Experimental Therapeutics

Two Novel 14-Epi-Analogues of 1,25-Dihydroxyvitamin D3 Inhibit the Growth of Human Breast Cancer Cells in Vitro and in Vivo1

Lieve Verlinden2, Annemieke Verstuyf2, Mark Van Camp, Suzanne Marcelis, Katrien Sabbe, Xu-Yang Zhao, Pierre De Clercq, Maurits Vandewalle and Roger Bouillon3

Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Katholieke Universiteit Leuven, 3000 Leuven [L. V., A. V., M. V. C., S. M., R. B.], and Vakgroep voor Organische Chemie, Universiteit Gent, 9000 Ghent [K. S., X-Y. Z., P. D. C., M. V.], Belgium

The biological activity of two novel 14-epi-analogues of 1,25(OH)2D3, 19-nor-14-epi-23-yne-1,25(OH)2D3 (TX 522) and 19-nor-14,20-bisepi-23-yne-1,25(OH)2D3 (TX 527), is described. Both analogues were at least 10 times more potent than 1,25(OH)2D3 in inhibiting in vitro cell proliferation and had much lower in vivo calcemic effects than 1,25(OH)2D3. Treatment with 1,25(OH)2D3, TX 522, or TX 527 in vitro was accompanied by an accumulation of cells in the G1 phase of the cell cycle. Protein levels of cyclin C and cyclin D1 in in vitro cultures of MCF-7 cells were down-regulated to 50 and 30%, respectively, of control levels at 72 and 120 h after stimulation. Protein levels of p21 and p27 at 72 h were significantly enhanced by 1,25(OH)2D3 and TX 522 but surprisingly not by TX 527. The inability of TX 527 to up-regulate p21 seemed to be cell type specific because p21 was induced in other cell types. Diminished phosphorylation of the retinoblastoma protein after treatment with 1,25(OH)2D3, TX 522, or TX 527 may ultimately contribute to the growth inhibition caused by these compounds. According to the data presented, the induction of apoptosis seemed not to be a major mechanism responsible for the growth-inhibitory effect of 1,25(OH)2D3 and analogues. Both 14-epi-analogues significantly retarded tumor progression (40% reduced compared with control mice) in an in vivo model of MCF-7 breast cancer cells established in nude mice. In conclusion, these novel analogues have the eligible profile to be tested as therapeutic agents for the treatment of hyperproliferative diseases such as breast cancer.




This article has been cited by other articles:


Home page
Nutr Clin PractHome page
G. E. Mullin and A. Dobs
Vitamin D and Its Role in Cancer and Immunity: A Prescription for Sunlight
Nutr Clin Pract, June 1, 2007; 22(3): 305 - 322.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Masuda and G. Jones
Promise of vitamin D analogues in the treatment of hyperproliferative conditions.
Mol. Cancer Ther., April 1, 2006; 5(4): 797 - 808.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
K. Khadzkou, P. Buchwald, G. Westin, H. Dralle, G. Akerstrom, and P. Hellman
25-Hydroxyvitamin D3 1{alpha}-Hydroxylase and Vitamin D Receptor Expression in Papillary Thyroid Carcinoma
J. Histochem. Cytochem., March 1, 2006; 54(3): 355 - 361.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Verlinden, G. Eelen, I. Beullens, M. Van Camp, P. Van Hummelen, K. Engelen, R. Van Hellemont, K. Marchal, B. De Moor, F. Foijer, et al.
Characterization of the Condensin Component Cnap1 and Protein Kinase Melk as Novel E2F Target Genes Down-regulated by 1,25-Dihydroxyvitamin D3
J. Biol. Chem., November 11, 2005; 280(45): 37319 - 37330.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Eelen, L. Verlinden, N. Rochel, F. Claessens, P. De Clercq, M. Vandewalle, G. Tocchini-Valentini, D. Moras, R. Bouillon, and A. Verstuyf
Superagonistic Action of 14-epi-Analogs of 1,25-Dihydroxyvitamin D Explained by Vitamin D Receptor-Coactivator Interaction
Mol. Pharmacol., May 1, 2005; 67(5): 1566 - 1573.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. G.S. van Halteren, E. van Etten, E. C. de Jong, R. Bouillon, B. O. Roep, and C. Mathieu
Redirection of Human Autoreactive T-Cells Upon Interaction With Dendritic Cells Modulated by TX527, an Analog of 1,25 Dihydroxyvitamin D3
Diabetes, July 1, 2002; 51(7): 2119 - 2125.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. Liu, S. L. Asa, I. G. Fantus, P. G. Walfish, and S. Ezzat
Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways
Am. J. Pathol., February 1, 2002; 160(2): 511 - 519.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
B. A. Scaglione-Sewell, M. Bissonnette, S. Skarosi, C. Abraham, and T. A. Brasitus
A Vitamin D3 Analog Induces a G1-Phase Arrest in CaCo-2 Cells by Inhibiting Cdk2 and Cdk6: Roles of Cyclin E, p21Waf1, and p27Kip1
Endocrinology, November 1, 2000; 141(11): 3931 - 3939.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. F. McGuire, D. L. Trump, and C. S. Johnson
Vitamin D3-induced Apoptosis of Murine Squamous Cell Carcinoma Cells. SELECTIVE INDUCTION OF CASPASE-DEPENDENT MEK CLEAVAGE AND UP-REGULATION OF MEKK-1
J. Biol. Chem., July 6, 2001; 276(28): 26365 - 26373.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2000 by the American Association for Cancer Research.